{"id":412813,"date":"2021-01-12T07:03:41","date_gmt":"2021-01-12T12:03:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412813"},"modified":"2021-01-12T07:03:41","modified_gmt":"2021-01-12T12:03:41","slug":"pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/","title":{"rendered":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress<\/b><\/p>\n<p>HAYWARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPulse Biosciences, Inc. (Nasdaq: PLSE) (\u201cPulse Biosciences\u201d or the \u201cCompany\u201d), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced CellFX<sup>\u00ae<\/sup> System regulatory progress updates.\n<\/p>\n<p><b>Recent CellFX System Highlights<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nReceived notification from the Food and Drug Administration (FDA) that the Company\u2019s 510(k) submission for a general dermatology indication for the CellFX System has advanced from Substantive Review to Interactive Review.\n<\/li>\n<li>\nCompleted all treatments in the Company\u2019s previously announced pivotal comparison study to evaluate the treatment of sebaceous hyperplasia (SH) using the CellFX System, with the planned specific indication 510(k) submission as early as the end of the first quarter of 2021.\n<\/li>\n<li>\nObtained FDA Investigational Device Exemption (IDE) approval of a pivotal comparison study to evaluate the treatment of cutaneous non-genital warts using the CellFX System, with enrollment expected to begin by the end of the first quarter of 2021.\n<\/li>\n<li>\nContinued review by the Notified Body of the CellFX System for CE mark approval and Health Canada for Medical Device License remains on track.\n<\/li>\n<\/ul>\n<p>\n\u201cWe are very pleased with the progress our team made throughout a challenging 2020 in advancing the CellFX System and in interactions with regulatory authorities in the US, European Union and Canada,\u201d said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. \u201cWe continue to work with the regulatory authorities in each of these geographies and appreciate the collaborative and timely interactions we have had during these reviews.\u201d\n<\/p>\n<p><b>About Pulse Biosciences<sup>\u00ae<\/sup><\/b><\/p>\n<p>\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. If cleared, the CellFX<sup>\u00ae<\/sup> System is the first commercial product to harness the distinctive advantages of the Company\u2019s proprietary Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. Subject to regulatory approval, the initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.\n<\/p>\n<p>\nPulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and\/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.\n<\/p>\n<p>\nCaution: Pulse Biosciences\u2019 CellFX System and Nano-Pulse Stimulation technology are considered for investigational use only.\n<\/p>\n<p><b>Forward-Looking Statements <\/b><\/p>\n<p>\nAll statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences\u2019 expectations regarding regulatory clearance and the timing of FDA, notified body, Health Canada and other regulatory body filings or approvals, and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for any specific indications, the ability of the Company to prepare and provide data to FDA, EU, Canadian and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company\u2019s market opportunity and commercialization plans, including the market for the treatment of certain lesions, future financial performance, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences\u2019 current expectations, estimates, and projections regarding Pulse Biosciences\u2019 business, operations and other similar or related factors. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences\u2019 control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences\u2019 filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210112005399\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210112005399\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<br \/><\/b>Pulse Biosciences<br \/>\n<br \/>Sandra Gardiner, EVP and CFO<br \/>\n<br \/>510.241.1077<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@pulsebiosciences.com\">IR@pulsebiosciences.com<br \/>\n<\/a><br \/>or<br \/>\n<br \/>Gilmartin Group<br \/>\n<br \/>Philip Trip Taylor<br \/>\n<br \/>415.937.5406<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:philip@gilmartinir.com\">philip@gilmartinir.com<\/a><\/p>\n<p><b>Media:<br \/>\n<br \/><\/b>Tosk Communications<br \/>\n<br \/>Nadine D. Tosk<br \/>\n<br \/>504.453.8344<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:nadinepr@gmail.com\">nadinepr@gmail.com<\/a> or<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@pulsebiosciences.com\">press@pulsebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Surgery Medical Devices Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE) (\u201cPulse Biosciences\u201d or the \u201cCompany\u201d), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced CellFX\u00ae System regulatory progress updates. Recent CellFX System Highlights Received notification from the Food and Drug Administration (FDA) that the Company\u2019s 510(k) submission for a general dermatology indication for the CellFX System has advanced from Substantive Review to Interactive Review. Completed all treatments in the Company\u2019s previously announced pivotal comparison study to evaluate the treatment of sebaceous hyperplasia (SH) using the CellFX System, with the planned specific indication 510(k) submission as early as the end of the first quarter of 2021. Obtained FDA Investigational &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412813","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE) (\u201cPulse Biosciences\u201d or the \u201cCompany\u201d), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced CellFX\u00ae System regulatory progress updates. Recent CellFX System Highlights Received notification from the Food and Drug Administration (FDA) that the Company\u2019s 510(k) submission for a general dermatology indication for the CellFX System has advanced from Substantive Review to Interactive Review. Completed all treatments in the Company\u2019s previously announced pivotal comparison study to evaluate the treatment of sebaceous hyperplasia (SH) using the CellFX System, with the planned specific indication 510(k) submission as early as the end of the first quarter of 2021. Obtained FDA Investigational &hellip; Continue reading &quot;Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T12:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress\",\"datePublished\":\"2021-01-12T12:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/\"},\"wordCount\":847,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/\",\"name\":\"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-12T12:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/","og_locale":"en_US","og_type":"article","og_title":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk","og_description":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211; Pulse Biosciences, Inc. (Nasdaq: PLSE) (\u201cPulse Biosciences\u201d or the \u201cCompany\u201d), a novel bioelectric medicine company progressing Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, today announced CellFX\u00ae System regulatory progress updates. Recent CellFX System Highlights Received notification from the Food and Drug Administration (FDA) that the Company\u2019s 510(k) submission for a general dermatology indication for the CellFX System has advanced from Substantive Review to Interactive Review. Completed all treatments in the Company\u2019s previously announced pivotal comparison study to evaluate the treatment of sebaceous hyperplasia (SH) using the CellFX System, with the planned specific indication 510(k) submission as early as the end of the first quarter of 2021. Obtained FDA Investigational &hellip; Continue reading \"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T12:03:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress","datePublished":"2021-01-12T12:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/"},"wordCount":847,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/","name":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-12T12:03:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210112005399r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-updates-on-cellfx-system-regulatory-and-clinical-study-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412813"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412813\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}